nach oben

Erschienen in:

01.06.2022 | News item

Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Use of denosumab 60mg (Prolia) is not safe in patients under 18 years of age because of the risk of serious hypercalcaemia, warns the UK Medicines and Healthcare products Regulatory Agency (MHRA). …

Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia Internet Document : 26 May 2022. Available from: URL: https://www.gov.uk/drug-safety-update/denosumab-60mg-prolia-should-not-be-used-in-patients-under-18-years-due-to-the-risk-of-serious-hypercalcaemia

Titel: Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia
Publikationsdatum: 01.06.2022
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-16290-8

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Tigecycline

Pyridostigmine/steroids

Amiodarone

Mycophenolate mofetil

Fentanyl

Biperiden/haloperidol